Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 4
Locations
Turkey
Study Type
Interventional
Intervention
S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Male or female outpatients 18 years and older.
- Hypertension patients have not received any anti-hypertensive treatment before ( ≥ 140 mmHg MSSBP < 160 mmHg, ≥ 90 mmHg MSDBP < 100mmHg).
- Hypertension patients controlled with single medicine.
- Patients giving written informed consent without being under any influence.
Exclusion Criteria:
- Pregnant patients, nursing mothers or female patients who have potential for childbearing and do not use any effective contraceptive method.
- Allergy or hypersensitivity to dihydropyridines.
- Patients receive more than one anti-hypertensive medicine.
- Patients with seconder hypertension.
- Patients with severe hypertension, myocardial infarction, NYHA stage 2-4 cardiac insufficiency, history of cerebrovascular disease, past ischemic attack, encephalopathy, underwent coronary artery bypass surgery or percutaneous coronary intervention, second or third degree heart block or symptomatic arrhythmia without pacemaker, clinically significant heart valve disease, potential life-threatening or symptomatic arrhythmia, simultaneous unstable angina pectoris, type I diabetes mellitus, atrial fibrillation until the last 12 months.
- Uncontrolled type II diabetes mellitus.
- Patients with significant liver disease (ALT, AST must be > 2XULN in beginning, patients with esophageal varices, portacaval shunt).
- Patients with significant kidney disease (GFR <60 ml/min according to Cockcroft-Gault formula).
- Patients with volume depletion.
- Patients with pancreas disease.
- Patients with gastrointestinal disease which may effect absorption.
- Drug/narcotic and alcohol abuse until the last 12 months.
- Patients with central nervous system disease and taking medicine for this reason.
- History of incompatibility with medical regimes or patients do not want to adhere the study protocol.
- Persons directly involved in the management of this protocol.
Sites / Locations
- Istanbul University Istanbul Medical Faculty Clinical Pharmacology Department
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
s-amlodipine besylate 2,5 and 5 mg tablets
Arm Description
Outcomes
Primary Outcome Measures
Evaluation of change in systolic blood pressure up to 4th week of the treatment
Secondary Outcome Measures
Evaluation of change in diastolic blood pressure up to 4th week of the treatment
Evaluation of change in diastolic blood pressure up to 8th week of the treatment
Evaluation of change in systolic blood pressure up to 8th week of the treatment
Evaluation of change in systolic blood pressure from 4th to 8th week of the treatment
Evaluation of change in diastolic blood pressure from 4th to 8th week of the treatment
Evaluation of treatment response rates from 4th to 8th week of the treatment
Full Information
NCT ID
NCT03038451
First Posted
January 14, 2017
Last Updated
June 13, 2018
Sponsor
Neutec Ar-Ge San ve Tic A.Ş
1. Study Identification
Unique Protocol Identification Number
NCT03038451
Brief Title
Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients
Official Title
Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients: Open-label, Local, Phase IV Study
Study Type
Interventional
2. Study Status
Record Verification Date
June 2018
Overall Recruitment Status
Completed
Study Start Date
March 20, 2013 (Actual)
Primary Completion Date
February 14, 2017 (Actual)
Study Completion Date
February 14, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Neutec Ar-Ge San ve Tic A.Ş
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
s-amlodipine besylate 2,5 mg tablet will be administered to patients have not received any hypertension treatment before or have received any of anti-hypertensive mono-therapy for the first four weeks of treatment. By increasing dose, s-amlodipine besylate 5 mg tablet will be administered for the last four weeks (4-8 weeks).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
43 (Actual)
8. Arms, Groups, and Interventions
Arm Title
s-amlodipine besylate 2,5 and 5 mg tablets
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet
Primary Outcome Measure Information:
Title
Evaluation of change in systolic blood pressure up to 4th week of the treatment
Time Frame
4 weeks
Secondary Outcome Measure Information:
Title
Evaluation of change in diastolic blood pressure up to 4th week of the treatment
Time Frame
4 weeks
Title
Evaluation of change in diastolic blood pressure up to 8th week of the treatment
Time Frame
8 weeks
Title
Evaluation of change in systolic blood pressure up to 8th week of the treatment
Time Frame
8 weeks
Title
Evaluation of change in systolic blood pressure from 4th to 8th week of the treatment
Time Frame
4 to 8 weeks
Title
Evaluation of change in diastolic blood pressure from 4th to 8th week of the treatment
Time Frame
4 to 8 weeks
Title
Evaluation of treatment response rates from 4th to 8th week of the treatment
Time Frame
4 to 8 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female outpatients 18 years and older.
Hypertension patients have not received any anti-hypertensive treatment before ( ≥ 140 mmHg MSSBP < 160 mmHg, ≥ 90 mmHg MSDBP < 100mmHg).
Hypertension patients controlled with single medicine.
Patients giving written informed consent without being under any influence.
Exclusion Criteria:
Pregnant patients, nursing mothers or female patients who have potential for childbearing and do not use any effective contraceptive method.
Allergy or hypersensitivity to dihydropyridines.
Patients receive more than one anti-hypertensive medicine.
Patients with seconder hypertension.
Patients with severe hypertension, myocardial infarction, NYHA stage 2-4 cardiac insufficiency, history of cerebrovascular disease, past ischemic attack, encephalopathy, underwent coronary artery bypass surgery or percutaneous coronary intervention, second or third degree heart block or symptomatic arrhythmia without pacemaker, clinically significant heart valve disease, potential life-threatening or symptomatic arrhythmia, simultaneous unstable angina pectoris, type I diabetes mellitus, atrial fibrillation until the last 12 months.
Uncontrolled type II diabetes mellitus.
Patients with significant liver disease (ALT, AST must be > 2XULN in beginning, patients with esophageal varices, portacaval shunt).
Patients with significant kidney disease (GFR <60 ml/min according to Cockcroft-Gault formula).
Patients with volume depletion.
Patients with pancreas disease.
Patients with gastrointestinal disease which may effect absorption.
Drug/narcotic and alcohol abuse until the last 12 months.
Patients with central nervous system disease and taking medicine for this reason.
History of incompatibility with medical regimes or patients do not want to adhere the study protocol.
Persons directly involved in the management of this protocol.
Facility Information:
Facility Name
Istanbul University Istanbul Medical Faculty Clinical Pharmacology Department
City
Istanbul
State/Province
Fatih
ZIP/Postal Code
34093
Country
Turkey
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
29649885
Citation
Sen S, Demir M, Yigit Z, Uresin AY. Efficacy and Safety of S-Amlodipine 2.5 and 5 mg/d in Hypertensive Patients Who Were Treatment-Naive or Previously Received Antihypertensive Monotherapy. J Cardiovasc Pharmacol Ther. 2018 Jul;23(4):318-328. doi: 10.1177/1074248418769054. Epub 2018 Apr 12.
Results Reference
result
Learn more about this trial
Efficacy and Safety of S-amlodipine 2,5 mg and 5 mg in Hypertension Patients
We'll reach out to this number within 24 hrs